ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors.

Daniel H. Palmer, Sarah P. Blagden, Silviya Balabanova et al.|Journal of Clinical Oncology|2024

Cited by 4